6
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Desaggregation by Verapamil, Sodium Nitroprusside and PGE1, of Rabbit Platelets Aggregated by PAF-acether. A Morphological and Biochemical Study

, , &
Pages 150-155 | Published online: 07 Jul 2009
 

Abstract

The action of sodium nitroprusside, an activator of guanylate cyclase, on rabbit platelets stimulated with PAF-acether, was studied singly or in combination with verapamil. Not only did sodium nitroprusside in the range 10−6 to 10−4 M inhibit PAF-acether induced aggregation, but it also brought about desaggregation of previously aggregated platelets, as also did verapamil. The results were compared with those obtained with PGE1, when used alone and in combination with verapamil. Morphological studies were carried out on control and aggregated platelets, and on platelets treated with verapamil either to inhibit aggregation or to bring about desaggregation. The platelets that had been desaggregated by verapamil were discoid in shape, had very few pseudopodia and exhibited a near normal internal morphology, except that the open canalicular system was swollen and contained an electron dense material resembling the contents of the alpha granules. The morphology of platelets desaggregated by PGE1 was similar to that of platelets desaggregated by verapamil, including a swollen canalicular system containing electron dense material.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.